glycine has been researched along with Immunoglobulin Light-chain Amyloidosis in 6 studies
Immunoglobulin Light-chain Amyloidosis: A nonproliferative disorder of the PLASMA CELL characterized by excessive production and misfolding of IMMUNOGLOBULIN LIGHT CHAINS that form insoluble amyloid fibrils (see AMYLOID DEPOSITS) in various tissues. Clinical features include LIVER FAILURE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; RESTRICTIVE CARDIOMYOPATHY, and neuropathies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1-2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85) or physician's choice (dexamethasone ± melphalan, cyclophosphamide, thalidomide, or lenalidomide; n = 83) in 28-day cycles until progression or toxicity." | 9.51 | A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. ( Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD, 2022) |
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 9.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| "In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1-2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85) or physician's choice (dexamethasone ± melphalan, cyclophosphamide, thalidomide, or lenalidomide; n = 83) in 28-day cycles until progression or toxicity." | 5.51 | A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. ( Berg, D; Comenzo, RL; Dispenzieri, A; Faller, DV; Kastritis, E; Kim, K; Kumar, A; Kwok, F; Landau, HJ; Liu, G; Merlini, G; Sanchorawala, V; Schönland, SO; Suzuki, K; Wechalekar, AD, 2022) |
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 5.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| " We report outcomes of 40 patients with relapsed AL amyloidosis treated with ixazomib + lenalidomide + dexamethasone (IRd)." | 3.96 | Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. ( Cheesman, S; Cohen, OC; Fontana, M; Gillmore, JD; Hawkins, PN; Kyriakou, C; Lachmann, HJ; Mahmood, S; Martinez-Naharro, A; Popat, R; Rabin, N; Sachchithanantham, S; Shah, R; Sharpley, F; Wechalekar, AD; Whelan, CJ; Yong, K, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosenbaum, CA | 1 |
| Özbek, U | 1 |
| Sanchez, L | 1 |
| Lagdameo, J | 1 |
| Abrahams, A | 1 |
| Hassoun, H | 1 |
| Lahoud, O | 1 |
| Niesvizky, R | 1 |
| Landau, HJ | 2 |
| Osman, K | 1 |
| Premkumar, V | 1 |
| Comenzo, R | 1 |
| Lentzsch, S | 1 |
| Cohen, OC | 1 |
| Sharpley, F | 1 |
| Gillmore, JD | 1 |
| Lachmann, HJ | 1 |
| Sachchithanantham, S | 1 |
| Mahmood, S | 1 |
| Fontana, M | 1 |
| Whelan, CJ | 1 |
| Martinez-Naharro, A | 1 |
| Kyriakou, C | 1 |
| Rabin, N | 1 |
| Popat, R | 1 |
| Yong, K | 1 |
| Cheesman, S | 1 |
| Shah, R | 1 |
| Hawkins, PN | 1 |
| Wechalekar, AD | 2 |
| Dispenzieri, A | 1 |
| Kastritis, E | 1 |
| Schönland, SO | 1 |
| Kim, K | 1 |
| Sanchorawala, V | 1 |
| Kwok, F | 1 |
| Suzuki, K | 1 |
| Comenzo, RL | 1 |
| Berg, D | 1 |
| Liu, G | 1 |
| Kumar, A | 1 |
| Faller, DV | 1 |
| Merlini, G | 1 |
| Joseph, NS | 1 |
| Kaufman, JL | 1 |
| Smolewski, P | 1 |
| Rydygier, D | 1 |
2 reviews available for glycine and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
Novel Approaches for the Management of AL Amyloidosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Boron Compounds; Glycine; Humans; Immunog | 2018 |
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Boron Compounds; Dexamethasone; Drugs, Investi | 2019 |
2 trials available for glycine and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis.
Topics: Boron Compounds; Cyclophosphamide; Dexamethasone; Glycine; Humans; Immunoglobulin Light-chain Amyloi | 2022 |
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyc | 2022 |
2 other studies available for glycine and Immunoglobulin Light-chain Amyloidosis
| Article | Year |
|---|---|
Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Bridged Bicyclo C | 2019 |
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dex | 2020 |